Ani Pharmaceuticals (ANIP) Net Cash Flow Growth (3y) (2013 - 2026)
Ani Pharmaceuticals (ANIP) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn | -19.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.52% |
| Mar 31, 2026 | 20.54% |
| Dec 31, 2025 | 71.25% |
| Sep 30, 2025 | 101.89% |
| Jun 30, 2025 | 90.98% |
| Mar 31, 2025 | 30.53% |
| Dec 31, 2024 | -85.27% |
| Sep 30, 2024 | -119.32% |
| Jun 30, 2024 | 153.01% |
| Mar 31, 2024 | -24.26% |
| Dec 31, 2023 | 68.62% |
| Sep 30, 2023 | 73.26% |
| Jun 30, 2023 | 134.47% |
| Mar 31, 2023 | 32.88% |
| Dec 31, 2022 | -71.26% |
| Sep 30, 2022 | -33.36% |
| Jun 30, 2022 | -97.61% |
| Mar 31, 2022 | -69.68% |
| Dec 31, 2021 | 327.02% |
| Sep 30, 2021 | 6.02% |